At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 41 enrolled
Drug / intervention
Palbociclib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b/2a Study Of Palbociclib In Combination With Everolimus And Exemestane In Postmenopausal Women With Estrogen Receptor Positive and HER2 Negative Metastatic Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Palbociclib, Everolimus, and 1 other intervention for Human Epidermal Growth Factor 2 Negative Carcinoma of Breast and Hormone Receptor (HR)-Positive Breast Cancer. Completed, enrolled 41 participants across 1 site.
Detailed Summary
This research study is studying a combination of targeted therapy and hormonal therapy as a possible treatment for breast cancer that has spread to other places in the body and is hormone receptor positive (HR+) and HER2-negative. The names of the study interventions involved in this study are: * Palbociclib * Everolimus * Exemestane
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor (HR)-Positive Breast Cancer
CountriesUnited States
CollaboratorsPfizer
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartAug 2016
Primary CompletionDec 2020
Study CompletionSep 2021
TodayJul 2026
First PostedAug 18, 2016
Enrollment StartAug 24, 2016
Primary CompletionDec 3, 2020
Study CompletionSep 1, 2021
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 9.9 years ago
Interventions
Palbociclibdrug
Everolimusdrug
Exemestanedrug